Pātiki and Waharua Kōpito patterns
|
Antigen(s) |
DTaP-IPV-HepB/Hib |
PCV13 |
MenB |
RV1 |
MMR |
Hib-PRP |
VV |
DTaP-IPV |
Tdap |
HPV9 |
Influenza |
rZV |
|
Brand name |
Infanrix-hexa |
Prevenar 13 |
Bexsero |
Rotarix |
Priorix |
Act-HIB |
Varilrix |
Infanrix-IPV |
Boostrix |
Gardasil 9 |
Influvac Tetra |
Shingrix |
|
Pregnancy |
|
|
|
|
|
|
|
|
Tdap |
|
Influenza |
|
|
6 weeks |
DTaP-IPV-HepB/Hib |
PCV13a |
|
RV1 |
|
|
|
|
|
|
|
|
|
3 months |
DTaP-IPV-HepB/Hib |
|
MenBb |
RV1 |
|
|
|
|
|
|
|
|
|
5 months |
DTaP-IPV-HepB/Hib |
PCV13 |
MenB |
|
|
|
|
|
|
|
|
|
|
12 months |
|
PCV13 |
MenB |
|
MMR |
|
|
|
|
|
|
|
|
15 months |
|
|
|
|
MMR |
Hib-PRP |
VV |
|
|
|
|
|
|
4 years |
|
|
|
|
|
|
|
DTaP-IPV |
|
|
|
|
|
11 or |
|
|
|
|
|
|
|
|
Tdap |
HPV9 |
|
|
|
45 years |
|
|
|
|
|
|
|
|
Tdap |
|
|
|
|
65 years |
|
|
|
|
|
|
|
|
Tdap |
|
Influenza |
rZV |
Key:
D = diphtheria; T = tetanus; aP = acellular pertussis; IPV = inactivated polio vaccine; HepB = hepatitis B; Hib = Haemophilus influenzae type b;
PCV13 = 13-valent pneumococcal conjugate vaccine; RV1 = rotavirus vaccine (monovalent); MenB = meningococcal B vaccine; MMR = measles, mumps and rubella; VV = varicella vaccine;
d = adult diphtheria; ap = adult acellular pertussis; HPV9 = human papillomavirus (9 serotypes); rZV = herpes zoster vaccine.
a. For children at high risk of pneumococcal disease, an additional dose of PCV13 is given at age 3 months.
b. An alternative approved schedule for MenB given at 8 weeks (2 months), 4 months and 12 months is available.
All individuals aged from 5 years are eligible to receive two doses of a COVID-19 vaccine. Additional doses are also available to different groups.